{"id":12649,"date":"2025-03-31T21:13:23","date_gmt":"2025-03-31T21:13:23","guid":{"rendered":"https:\/\/fusionmindlabs.com\/blogs\/isomorphic-labs-raises-600m\/"},"modified":"2025-03-31T21:13:23","modified_gmt":"2025-03-31T21:13:23","slug":"isomorphic-labs-raises-600m","status":"publish","type":"post","link":"https:\/\/fusionmindlabs.com\/blogs\/isomorphic-labs-raises-600m\/","title":{"rendered":"Isomorphic Labs raises $600M"},"content":{"rendered":"\n<\/p>\n<div>\n<p id=\"speakable-summary\" class=\"wp-block-paragraph\">Isomorphic Labs, an AI-driven platform for drug discovery that originated from Google&#8217;s DeepMind in 2021, has secured its first external funding. The company has raised $600 million in a round led by Thrive Capital, with additional investment from GV and its existing backer, Alphabet, the parent company of Google, <a rel=\"nofollow noopener\" href=\"https:\/\/www.isomorphiclabs.com\/articles\/isomorphic-labs-announces-600m-external-investment-round\" target=\"_blank\">as announced<\/a>. \u00a0\u00a0\u00a0<\/p>\n<p class=\"wp-block-paragraph\">This new funding will be utilized to further enhance Isomorphic&#8217;s AI-powered drug design capabilities and facilitate the progression of its discovered drugs into clinical trials.<\/p>\n<p class=\"wp-block-paragraph\">Isomorphic Labs was established by Demis Hassabis, a co-founder of DeepMind, leveraging the AI drug discovery software developed by DeepMind, including AlphaFold. AlphaFold is an AI model renowned for its ability to predict the three-dimensional structures of proteins.<\/p>\n<p class=\"wp-block-paragraph\">In the previous year, Isomorphic Labs formed strategic partnerships with pharmaceutical giants Eli Lilly and Novartis, which could potentially yield up to $3 billion in milestone payments in exchange for access to its AI technology, <a target=\"_blank\" href=\"https:\/\/techcrunch.com\/2024\/01\/07\/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery\/\" rel=\"noreferrer noopener nofollow\">as reported<\/a>.<\/p>\n<p class=\"wp-block-paragraph\">According to Demis Hassabis, as stated in an interview with <a target=\"_blank\" href=\"https:\/\/www.nytimes.com\/2025\/03\/31\/business\/dealbook\/isomorphic-google-thrive-investment.html\" rel=\"noreferrer noopener nofollow\">The New York Times<\/a>, although Isomorphic Labs did not necessarily require the additional capital, the funding will enable the company to recruit top-tier research scientists.<\/p>\n<p class=\"wp-block-paragraph\">Hassabis, along with DeepMind researcher John Jumper, was among the recipients of the <a href=\"https:\/\/www.nobelprize.org\/prizes\/chemistry\/2024\/press-release\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">2024 Nobel Prize in Chemistry<\/a> for their groundbreaking work on AlphaFold.<\/p>\n<\/div>\n\n<br \/><a href=\"https:\/\/techcrunch.com\/2025\/03\/31\/alphabets-ai-drug-discovery-platform-isomorphic-labs-raises-600m-from-thrive\/\" rel=\"nofollow noopener\" target=\"_blank\">Source Link<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Isomorphic Labs, an AI-driven platform for drug discovery that originated from Google&#8217;s DeepMind in 2021, has secured its first external funding. The company has raised $600 million in a round&#8230;<\/p>\n","protected":false},"author":0,"featured_media":12650,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[47],"tags":[3936,815,777,3935],"class_list":["post-12649","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","tag-ai-drug-discovery","tag-alphabet","tag-deepmind","tag-isomorphic-labs"],"jetpack_featured_media_url":"https:\/\/fusionmindlabs.com\/blogs\/wp-content\/uploads\/sites\/9\/2025\/03\/gettyimages-450853983.jpg","_links":{"self":[{"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/posts\/12649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/comments?post=12649"}],"version-history":[{"count":0,"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/posts\/12649\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/media\/12650"}],"wp:attachment":[{"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/media?parent=12649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/categories?post=12649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fusionmindlabs.com\/blogs\/wp-json\/wp\/v2\/tags?post=12649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}